Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KYTX

Kyverna Therapeutics Inc.

Last Close
Sep 13 • 04:00PM ET
7.20
Dollar change
+0.21
Percentage change
3.00 		%
Held by: VTI IWM VXF IWO VTWO SCHA IWN IWC SBIO VTWG Scroll to Statements
IndexRUT P/E- EPS (ttm)-2.63 Insider Own59.03% Shs Outstand43.12M Perf Week-1.91%
Market Cap310.68M Forward P/E- EPS next Y-4.00 Insider Trans0.00% Shs Float17.68M Perf Month6.67%
Income-91.63M PEG- EPS next Q-0.76 Inst Own37.38% Short Float15.17% Perf Quarter-50.14%
Sales0.00M P/S- EPS this Y96.28% Inst Trans- Short Ratio4.41 Perf Half Y-75.63%
Book/sh7.73 P/B0.93 EPS next Y-19.96% ROA- Short Interest2.68M Perf Year-
Cash/sh8.02 P/C0.90 EPS next 5Y- ROE- 52W Range6.30 - 35.06 Perf YTD-76.00%
Dividend Est.- P/FCF- EPS past 5Y- ROI-26.98% 52W High-79.46% Beta-
Dividend TTM- Quick Ratio14.86 Sales past 5Y-37.90% Gross Margin- 52W Low14.29% ATR (14)0.62
Dividend Ex-Date- Current Ratio14.86 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)43.82 Volatility6.25% 7.93%
Employees96 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price41.25
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-119.89% Payout- Rel Volume0.40 Prev Close6.99
Sales Surprise- EPS Surprise4.05% Sales Q/Q- EarningsAug 12 AMC Avg Volume608.00K Price7.20
SMA20-4.64% SMA50-11.08% SMA200-54.23% Trades Volume244,242 Change3.00%
Date Action Analyst Rating Change Price Target Change
Jul-03-24Initiated H.C. Wainwright Neutral $8
Mar-04-24Initiated Wells Fargo Overweight $44
Mar-04-24Initiated Morgan Stanley Overweight $40
Mar-04-24Initiated Leerink Partners Outperform $48
Mar-04-24Initiated JP Morgan Overweight $39
Aug-21-24 04:05PM
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
(PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
(PR Newswire) +7.20%
04:05PM
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
(PR Newswire)
Jul-16-24 11:33AM
Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate
(Pharmaceutical Technology) +11.71%
08:52AM
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
(Zacks)
04:05PM Loading…
Jul-15-24 04:05PM
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
(PR Newswire)
Jun-20-24 08:55AM
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
(PR Newswire) +7.93%
Jun-17-24 04:05PM
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
(PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
(PR Newswire)
Jun-07-24 08:55AM
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
(PR Newswire)
May-14-24 10:54PM
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024
(InvestorPlace) +5.95%
04:05PM
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
(PR Newswire)
Apr-11-24 05:01PM
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
(PR Newswire)
Mar-29-24 02:59PM
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
(PR Newswire)
Mar-26-24 04:05PM
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
(PR Newswire) +6.97%
07:00AM Loading…
Mar-14-24 07:00AM
Why That Hot Biotech IPO Could Be a Winner
(The Wall Street Journal)
Mar-07-24 07:26PM
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
(PR Newswire)
06:14PM
How Kyverna is positioned for success on autoimmune therapy: CEO
(Yahoo Finance Video)
Feb-12-24 04:39PM
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
(PR Newswire)
Feb-07-24 10:29PM
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
(PR Newswire)
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karen MarieChief Technology OfficerJun 06 '24Option Exercise4.429,63642,5919,636Jun 10 06:56 PM
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM
Vida Ventures, LLC10% OwnerFeb 12 '24Buy22.00253,1365,568,992252,553Feb 14 07:04 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.